5.26
+0.0031(+0.06%)
Currency In USD
Address
3525 Del Mar Heights Road
San Diego, CA 92130
United States of America
Phone
858 800 2543
Website
Sector
Healthcare
Industry
Biotechnology
Employees
8
First IPO Date
August 13, 2021
| Name | Title | Pay | Year Born |
| Mr. Gerald T. Proehl | Founder, President, Chief Executive Officer & Chairman | 397,600 | 1959 |
| Dr. Maria Bedoya Toro Munera M.B.A., Ph.D. | Senior Vice President of Regulatory Affairs & Quality Assurance | 27,040 | 1952 |
| Mr. David F. Hale | Co-Founder & Lead Independent Director | 73,000 | 1949 |
| Ms. Kyri K. Van Hoose CPA, M.B.A. | Senior Vice President & Chief Financial Officer | 438,876 | 1979 |
| Dr. Christopher J. Nardo M.P.H., Ph.D. | Senior Vice President & Chief Development Officer | 466,932 | 1966 |
| Mr. Sean Proehl | Associate General Counsel | 0 | N/A |
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered in San Diego, California.